In this episode, the team discusses the emerging gray market for medical peptides, highlighting popular compounds like BPC-157, GLP-1 alternatives, and next-generation weight-loss therapies like retatrutide. They unpack the ongoing FDA Pharmacy Compounding Advisory Committee meeting, evaluating the regulatory push-and-pull around allowing 503A compounding pharmacies to produce these compounds safely in the U.S. Finally, the team breaks down the commercial landscape for telehealth platforms like HIMSS, analyzing the hurdles of patient adoption, the role of placebo effects in subjective treatments, and the timeline for these therapies to reach a regulated market.
This podcast is prepared and distributed by AMI Asset Management (AMI), an SEC-registered investment adviser (registration does not imply a certain level of skill or training). The information contained herein, and the opinions expressed are those of AMI as of the date of writing, prepared solely for general informational and discussion purposes. The information contained in this podcast has been compiled by AMI from sources believed to be reliable; however, AMI does not make any representation as to their accuracy, completeness or correctness and does not accept liability for any loss arising from the use hereof. Such information and opinions are subject to change without notice due to changes in market or economic conditions and may not necessarily come to pass. References to specific securities are not intended as recommendations of said securities. Please note that some of the securities mentioned may be held in an AMI strategy or in personal accounts. The reader should not assume that any investments in securities, sectors and markets identified or described were or will be profitable. Investing entails risks, including possible loss of principal. Past performance is not a guide to future performance and future returns are not guaranteed. The investment strategies referenced may not be suitable or appropriate for all investors depending on their specific investment objectives and financial situation and potential investors should consult with their own financial professional before determining whether to invest in the strategy.